Cannara Biotech Balance Sheet Health

Financial Health criteria checks 3/6

Cannara Biotech has a total shareholder equity of CA$81.9M and total debt of CA$47.9M, which brings its debt-to-equity ratio to 58.5%. Its total assets and total liabilities are CA$144.8M and CA$63.0M respectively. Cannara Biotech's EBIT is CA$14.0M making its interest coverage ratio 3.2. It has cash and short-term investments of CA$2.6M.

Key information

58.5%

Debt to equity ratio

CA$47.88m

Debt

Interest coverage ratio3.2x
CashCA$2.64m
EquityCA$81.86m
Total liabilitiesCA$62.96m
Total assetsCA$144.82m

Recent financial health updates

Recent updates

Here's Why We Think Cannara Biotech (CVE:LOVE) Might Deserve Your Attention Today

Feb 28
Here's Why We Think Cannara Biotech (CVE:LOVE) Might Deserve Your Attention Today

Investor Optimism Abounds Cannara Biotech Inc. (CVE:LOVE) But Growth Is Lacking

Jan 24
Investor Optimism Abounds Cannara Biotech Inc. (CVE:LOVE) But Growth Is Lacking

Cannara Biotech's (CVE:LOVE) Earnings May Just Be The Starting Point

Dec 18
Cannara Biotech's (CVE:LOVE) Earnings May Just Be The Starting Point

Is Cannara Biotech (CVE:LOVE) A Risky Investment?

Jul 29
Is Cannara Biotech (CVE:LOVE) A Risky Investment?

Cannara Biotech Inc.'s (CVE:LOVE) Business Is Yet to Catch Up With Its Share Price

Apr 10
Cannara Biotech Inc.'s (CVE:LOVE) Business Is Yet to Catch Up With Its Share Price

Here's Why Cannara Biotech (CVE:LOVE) Has A Meaningful Debt Burden

Jan 26
Here's Why Cannara Biotech (CVE:LOVE) Has A Meaningful Debt Burden

Cannara Biotech's (CVE:LOVE) Earnings Aren't As Good As They Appear

Jan 27
Cannara Biotech's (CVE:LOVE) Earnings Aren't As Good As They Appear

Cannara Biotech (CVE:LOVE) Has A Somewhat Strained Balance Sheet

Dec 10
Cannara Biotech (CVE:LOVE) Has A Somewhat Strained Balance Sheet

Here's Why Cannara Biotech (CSE:LOVE) Can Afford Some Debt

Mar 16
Here's Why Cannara Biotech (CSE:LOVE) Can Afford Some Debt

Can You Imagine How Cannara Biotech's (CSE:LOVE) Shareholders Feel About The -6.5% Share Price Increase?

Jan 22
Can You Imagine How Cannara Biotech's (CSE:LOVE) Shareholders Feel About The -6.5% Share Price Increase?

Have Insiders Been Buying Cannara Biotech Inc. (CSE:LOVE) Shares?

Dec 18
Have Insiders Been Buying Cannara Biotech Inc. (CSE:LOVE) Shares?

Financial Position Analysis

Short Term Liabilities: LOVE's short term assets (CA$52.8M) exceed its short term liabilities (CA$22.3M).

Long Term Liabilities: LOVE's short term assets (CA$52.8M) exceed its long term liabilities (CA$40.7M).


Debt to Equity History and Analysis

Debt Level: LOVE's net debt to equity ratio (55.3%) is considered high.

Reducing Debt: LOVE's debt to equity ratio has increased from 53.2% to 58.5% over the past 5 years.

Debt Coverage: LOVE's debt is not well covered by operating cash flow (12.8%).

Interest Coverage: LOVE's interest payments on its debt are well covered by EBIT (3.2x coverage).


Balance Sheet


Discover healthy companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.